Poland· PL-100424790

LysaKare

A arginin und lysin product containing l-lysini hydrochloridum + l-arginini hydrochloridum, registered in Poland by Advanced Accelerator Applications. The same ATC class is registered in 8 of our 19 countries.

ATC V03AF11

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedLysaKareATCV03AF11REGISTER NO.PL-100424790PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Arginin und lysin is registered in 8 of 19 countries.

Countries holding a registration under ATC V03AF11 (arginin und lysin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose

Arginin und lysin · ATC V03AF11

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
L-Lysini hydrochloridum + L-Arginini hydrochloridum
Manufacturer
Advanced Accelerator Applications
Country
Poland (PL)
ATC code
V03AF11
ATC class
Arginin und Lysin
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    03665808000033

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Arginin und lysin in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All arginin und lysin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Lysakare
  • Liechtenstein · Lysakare
  • Norway · Lysakare

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e6983283-87fb-44ac-934d-1bfa3d67e460
GET /v1/drugs/e6983283-87fb-44ac-934d-1bfa3d67e460?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do infuzji",
  "source": "urpl",
  "strength": "(25 mg + 25 mg)/ml",
  "packaging": "Rpz ¦ EU/1/19/1381/001 ¦ 134047\n1 worek 1000 ml\n¦ UR/Z/4c/109/24 - 03665808000033 ¦ UR/Z/4c/175/23 - 03665808000033 ¦ UR/Z/4c/014/25 - 03665808000033 ¦ UR/Z/4c/022/23 - 03665808000033 ¦ UR/Z/4c/118/25 - 03665808000033 ¦ UR/Z/4c/202/25 - 03665808000033 ¦ UR/Z/4c/304/25 - 03665808000033 ¦ UR/Z/4c/208/26",
  "substance": "L-Lysini hydrochloridum 25 mg/ml + L-Arginini hydrochloridum 25 mg/ml",
  "common_name": "L-Lysini hydrochloridum + L-Arginini hydrochloridum",
  "pl_product_id": "100424790",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about arginin und lysin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.